Skip to main content
SpringerLink
Log in

Laboratory Support

  • Chapter
  • First Online:
Establishing a Hematopoietic Stem Cell Transplantation Unit

  • 769 Accesses

Abstract

Hematopoietic stem cell transplantation (HSCT) offers high cure rates for patients with hematologic and oncologic diseases. The administration of intensified treatment during HSCT, resulting in marrow aplasia associated with infectious and bleeding complications and immunologic reactions such as graft-versus-host disease, is associated with substantial morbidity and mortality. The availability of appropriate laboratory facilities ensures the early detection of transplant complications, allowing pre-emptive measures and timely therapeutic interventions aiming at reducing HSCT risks. Standardized laboratory analyses improve the safety of blood products and allow appropriate donor selection, thus avoiding blood-transmissible diseases. To reduce relapse risk after HSCT, the assessment of minimal residual disease enables timely therapeutic measures to be taken to eradicate malignant cells in the long term.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Van Belkum A, Tassios PT, Dijkshoorn L, Haeggman S, Cookson B, Fry NK, Fussing V, Green J, Feil E, Gerner-Smidt P, Brisse S, Struelens M. Guidelines for the validation and application of typing methods for use in bacterial epidemiology. Clin Microbiol Inf Dis. 2007;13(Suppl 3):1–46.

    Google Scholar 

  2. Bochner BR. Advances in the identification of bacteria and yeast. Am Clin Lab. 1993;12:6.

    CAS  PubMed  Google Scholar 

  3. Di Giovanni GD, Watrud LS, Seidler RJ, Widmer F. Fingerprinting of mixed bacterial strains and BIOLOG gramnegative (GN) substrate communities by enterobacterial repetitive intergenic consensus sequence PCR (ERIC-PCR). Curr Microbiol. 1999;38:217–23.

    Article  PubMed  Google Scholar 

  4. Frasch CE. Serogroup and serotype classification of bacterial pathogens. Methods Enzymol. 1994;235:159–74.

    Article  CAS  PubMed  Google Scholar 

  5. Maslow JN, Ellis J, Mulligan M, Arbeit R. Molecular epidemiology: application of contemporary techniques to the typing of microorganisms. Clin Infect Dis. 1993;17:153–64.

    Article  CAS  PubMed  Google Scholar 

  6. Mayer LW. Use of plasmid profiles in epidemiologic surveillance of disease outbreaks and in tracing the transmission of antibiotic resistance. Clin Microbiol Rev. 1988;1:228–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Clarke SC. Nucleotide sequence based typing of bacteria and the impact of automation. Bioessays. 2002;24:858–62.

    Article  CAS  PubMed  Google Scholar 

  8. Gutacker MM, Smoot JC, Migliaccio CA, et al. Genome-wide analysis of synonymous single nucleotide polymorphisms in Mycobacterium tuberculosis complex organisms: resolution of genetic relationships among closely related microbial strains. Genetics. 2002;162:1533–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Zhang W, Qi W, Albert TJ, et al. Probing genomic diversity, evolution of Escherichia coli O157 by single nucleotide polymorphisms. Genome Res. 2006;16:757–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Park BJ, Pappas PG, Wannemuehler KA, Alexander BD, Anaissie EJ,Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt L, Ito JI, Kauffman CA, Lyon GM, Marr KA, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wingard JR, Walsh TJ, Kontoyiannis DP. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg. Infect. Dis. 2011;17:1855–64. http://dx.doi.org/10.3201/eid1710.110087.

  11. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–73.

    Article  CAS  PubMed  Google Scholar 

  12. Ullmann A, Lipton J, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.

    Article  CAS  PubMed  Google Scholar 

  13. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24:247–80.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O. Third European Conference on Leukemia. Beta-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43.

    Article  PubMed  Google Scholar 

  15. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Badley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100.

    Article  PubMed  Google Scholar 

  16. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, Chiba S, Motokura T, Hirai H, Ogawa S. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1-3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol. 2004;42:2733–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis. 2004;39:199–205.

    Article  CAS  PubMed  Google Scholar 

  18. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762–9.

    Article  CAS  PubMed  Google Scholar 

  19. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4:349–57.

    Article  CAS  PubMed  Google Scholar 

  20. D’Haese J, Theunissen K, Vermeulen E, Schoemans H, De Vlieger G, Lammertijn L, Meersseman P, Meersseman W, Lagrou K, Maertens J. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol. 2012;50:1258–63.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, Verbeken E, Verhoef G, Van Eldere J, Lagrou K. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688–93.

    Article  PubMed  Google Scholar 

  22. LaRocque RC, Katz JT, Perruzzi P, Baden LR. The utility of sputum induction for diagnosis of Pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus. Clin Infect Dis. 2003;37:1380–3.

    Article  PubMed  Google Scholar 

  23. Harris JR, Marston BJ, Sangrujee N, DuPlessis D, Park B. Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP). PLoS One. 2011;6:e23158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Karageorgopoulos DE, Qu JM, Korbila IP, Zhu YG, Vasileiou VA, Falagas ME. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect. 2013;19:39–49.

    Article  CAS  PubMed  Google Scholar 

  25. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S, European Conference on Infections in Leukemia Laboratory Working Group. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2012;47:846–54.

    Article  CAS  PubMed  Google Scholar 

  26. Ruchel R. Diagnosis of invasive mycoses in severely immunosuppressed patients. Ann Hematol. 1993;67:1–11.

    Article  CAS  PubMed  Google Scholar 

  27. Maaroufi Y, Heymans C, De Bruyne JM, Duchateau V, Rodriguez-Villalobos H, Aoun M, Crokaert F. Rapid detection of Candida albicans in clinical blood samples by using a TaqMan-based PCR assay. J Clin Microbiol. 2003;41:3293–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490–526. doi: 10.1128/CMR 00091–13.

  29. White PL, Bretagne S, Klingspor L, Melchers WJ, McCulloch E, Schulz B, Finnstrom N, Mengoli C, Barnes RA, Donnelly JP, Loeffler J, European Aspergillus PCR Initiative. Aspergillus PCR: one step closer to standardization. J Clin Microbiol. 2010;48:1231–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. White PL, Perry MD, Loeffler J, Melchers W, Klingspor L, Bretagne S, McCulloch E, Cuenca-Estrella M, Finnstrom N, Donnelly JP, Barnes RA, European Aspergillus PCR Initiative. Critical stages of extracting DNA from Aspergillus fumigatus in whole-blood specimens. J Clin Microbiol. 2010;48:3753–5.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Balashov SV, Park S, Perlin DS. Assessing resistance to the echocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother. 2006;50:2058–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Badiee P, Kordbacheh P, Alborzi A, Malekhoseini S, Zeini F, Mirhendi H, Mahmoodi M. Prospective screening in liver transplant recipients by panfungal PCR-ELISA for early diagnosis of invasive fungal infections. Liver Transpl. 2007;13:1011–6.

    Article  PubMed  Google Scholar 

  33. Sugawara Y, Nakase K, Nakamura A, Ohishi K, Sugimoto Y, Fujieda A, Monma F, Suzuki K, Masuya M, Matsushima Y, Wada H, Nobori T, Katayama N. Clinical utility of a panfungal polymerase chain reaction assay for invasive fungal diseases in patients with haematologic disorders. Eur J Haematol. 2013;90:331–9.

    Article  CAS  PubMed  Google Scholar 

  34. Wilson DA, Joyce MJ, Hall LS, Reller LB, Roberts GD, Hall GS, Alexander BD, Procop GW. Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for characterization of yeast isolates from blood cultures. J Clin Microbiol. 2005;43:2909–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, Hou JL, Wen YM, Nanj A, Liang R. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.

    Article  CAS  PubMed  Google Scholar 

  36. Hsiao LT, Chiou TJ, Gau JP, Liu JH, Tzeng CH, Chen PM. Hepatitis B infection in haematopoietic stem cell transplantation: still unresolved. Hong Kong Med J. 2009;15:42–4.

    CAS  PubMed  Google Scholar 

  37. Liang TJ, Baruch Y, Ben-Porath E, Enat R, Bassan L, Brown NV, Rimon N, Blum HE, Wands JR. Hepatitis B virus infestion in patients with idiopathic liver disease. Hepatology. 1991;13:1044–51.

    CAS  PubMed  Google Scholar 

  38. Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol. 2015;21(14):4284–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. FACT-JACIE. International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration. 6th ed. 2015. http://www.jacie.org/news/newinterimstandardstocoveradministrationofimmuneeffectorcellproductsinbonemarrowtransplantationprogrammes/Manual%206.01%20ed.pdf.

  40. Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE. Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. Bone Marrow Transplant. 2014;49:880–6.

    Article  CAS  PubMed  Google Scholar 

  41. WHO. Screening donated blood for transfusion-transmissible infections: recommendations. Geneva: World Health Organization; 2010. p. 1–66.

    Google Scholar 

  42. Laperche S. Antigen-antibody combination assays for blood donor screening: weighing the advantages and costs. Transfusion. 2008;48:576–9.

    Article  PubMed  Google Scholar 

  43. Busch MP, Glynn SA, Stramer SL. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion. 2005;45:254–64.

    Article  PubMed  Google Scholar 

  44. FDA Guidance for Industry. Nucleic acid testing (NAT) for human immunodeficiency virus type (HIV-1) and hepatitis C virus (HCV): testing, requirements for communicable disease agents. 2010, May 20.

    Google Scholar 

  45. Galel SA. Chapter 8, Infectious disease screening. In:AABB technical manual. 17th ed. Bethesda: AABB; 2011. p. 239–70.

    Google Scholar 

  46. Alsuhaibani O, Pereira WC, Tareeqanwar M, El Khizzi N, Bakheswain S, Shaker A, Elyamany G. Infectious disease screening among stem cell transplant donors: an institutional experience in Saudi Arabia. Ann Neurosci. 2015;22(2):81–6.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Olotu AM, Oyelese AO, Salawu L, Audu RA, Okwuraiwe AP, Aboderin AO. Occult hepatitis B virus infection in previously screened blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation. Virol J. 2016;13:76–83.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Arora S, Doda V, Kirtania T. Sensitivity of individual donor nucleic acid testing (NAT) for the detection of hepatitis B infection by studying diluted NAT yield samples. Blood Transfus. 2015;13(2):227–33.

    PubMed  PubMed Central  Google Scholar 

  49. Pruett CR, Vermeulen M, Zacharias P, Ingram C, Tagny CT, Bloch EM. The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. Transfus Med Rev. 2015;29(1):35–44.

    Article  PubMed  Google Scholar 

  50. UNICEF. HIV diagnosis: a guide for selecting rapid diagnostic test (RDT) kits. New York: UNICEF; 2008. p. 1–20.

    Google Scholar 

  51. WHO. Guidelines for using HIV testing technologies in surveillance: selection, evaluation, and implementation—2009 update. Geneva: WHO; 2009. p. 1–52.

    Google Scholar 

  52. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation. 1997;64:108–13.

    Article  CAS  PubMed  Google Scholar 

  53. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Löffler J, Wagner S, Müller CA. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815–20.

    CAS  PubMed  Google Scholar 

  54. Oellerich M, Armstrong VW, Khan B, Shaw L, Holt DW, Yatscoff R, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 1995;17:642–54.

    Article  CAS  PubMed  Google Scholar 

  55. Abendroth D. Experience with therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:426S–9S.

    Article  CAS  PubMed  Google Scholar 

  56. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36:420S–5S.

    Article  CAS  PubMed  Google Scholar 

  57. Bieglmayer C, Chan DW, Sokoll L, Imdahl R, Koayashi M, Yamada E, Likje DJ, Luthe H, Meissner J, Messeri G, Celli A, Tozzi P, Roth HJ, Schmidt FP, Mächler ML, Schuff-Werner P, Zingler C, Smitz J, Schiettecatte J, Vonderschmitt DJ, Pei P, Ng K, Ebert C, Kirch P, Wanger M, McGovern M, Stockmann W, Kunst A. Multicentre performance evaluation of the E170 module for modular analytics. Clin Chem Lab Med. 2004;42:1186–202.

    Article  CAS  PubMed  Google Scholar 

  58. Jourdil JF, Picard P, Meunier C, Auger S, Stanke-Labesque F. Ultra-fast cyclosporin A quantitation in whole blood by Laser Diode Thermal Desorption—tandem mass spectrometry; comparison with High Performance Liquid Chromatography-tandem mass spectrometry. Anal Chim Acta. 2013;805:80–6.

    Article  CAS  PubMed  Google Scholar 

  59. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood. 1991;77:400–9.

    CAS  PubMed  Google Scholar 

  60. Siena S, Bregni M, Brando M, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte macrophage colony-stimulating factor. Blood. 1989;74:1905–14.

    CAS  PubMed  Google Scholar 

  61. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213–26.

    Article  CAS  PubMed  Google Scholar 

  62. Gratama JW, Orfao A, Barnett D, Brando B, Huber A, Janossy G, et al. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry. 1998;34:128–42.

    Article  CAS  PubMed  Google Scholar 

  63. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry. 1998;34:61–70.

    Article  CAS  PubMed  Google Scholar 

  64. Dmytrus J, Matthes-Martin S, Pichler H, Worel N, Geyeregger R, Frank N, Frech C, Fritsch G. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant. 2016;51:1093–100.

    Article  CAS  PubMed  Google Scholar 

  65. Short NJ, Kantarjian HM, Jabbour EJ, O’Brien SM, Faderl S, Burger JA, Garris R, Quiao W, Huang X, Jain N, Konopleva M, Kadia TM, Daver N, Borthakur G, Cortes JE, Ravandi F. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016;91(4):385–9.

    Article  PubMed  Google Scholar 

  66. Vidriales MB, Perez-Lopez E, Pegenaute C, Castellanos M, Perez JJ, Chandia M, Diaz-Mediavilla J, Rayon C, de Las HN, Fernandez-Abellan P, Cabezudo M, de Coca AG, Alonso JM, Olivier C, Hernandez-Rivas JM, Montesinos P, Fernandez R, Garcia-Suarez J, Garcia M, Sayas MJ, Paiva B, Gonzalez M, Orfao A, San Miguel JF. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukemia. Leuk Res. 2016;40:1–9.

    Article  PubMed  Google Scholar 

  67. Chandrashekar V, Tarigopula A, Govindasami P. Cytogenetic profiling by FISH microscopy and comparison with light microscopy and complete blood count findings in myelodysplastic syndrome. J Microsc. 2016;265(1):94–100. doi:10.1111/jmi.12467.

    Article  PubMed  Google Scholar 

  68. Hu L, Ru K, Zhang L, Huang Y, Zhu X, Liu H, Zetterberg A, Cheng T, Miao W. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomarker Res. 2014;2:3.

    Article  Google Scholar 

  69. Wawrzyniak E, Kotkowska A, Blonski JZ, Siemieniuk-Rys M, Ziolkowska E, Giannopoulos K, Robak T, Korycka-Wolowiec A. Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. Eur J Haematol. 2014;92:91–101.

    Article  PubMed  Google Scholar 

  70. Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martin-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosinol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, van Dongen JJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San Miguel JF. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127(25):3165–74.

    Article  CAS  PubMed  Google Scholar 

  71. Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, Huang X, Daver N, DiNardo C, Andreeff M, Konopleva M, Estrov Z, Garcia-Manero G, Cortes J, Kantarjian H. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2016;123(3):426–35. doi:10.1002/cncr.30361.

    Article  PubMed  Google Scholar 

  72. Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, Bottcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonca A, de Tute R, Cullen M, Sedek L, Vidriales MB, Perez JJ, te Marvelde JG, Mejstrikova E, Hrusak O, Szczepanski T, van Dongen JJM, Orfao A. Euroflow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986–2010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, Sobral da Costa E, Kotrova M, Novakova M, Sonneveld E, Buracchi C, Bonaccorso P, Oliviera E, Te Marvelde JG, Szczepanski T, Lhermitte L, Hrusak O, Lecrevisse Q, Grigore GE, Fronkova E, Trka J, Brüggemann M, Orfao A, van Dongen JJ, van der Velden VH. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2016;129(3):347–57. doi:10.1182/blood-2016-07-726307.

    Article  PubMed  Google Scholar 

  74. Asnafi V, Rubio MT, Delabesse E, Villar E, Davi F, Damaj G, Hirsch I, Dhédin N, Vernant JP, Varet B, Buzyn A, Macintyre E. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia. 2006;20(5):793–9.

    Google Scholar 

  75. Tonegawa S. Somatic generation of antibody diversity. Nature. 1983;302(5909):575–81.

    Article  CAS  PubMed  Google Scholar 

  76. Salson M, Giraud M, Caillault A, Grardel N, Duployez N, Ferret Y, Duez M, Herbert R, Rocher T, Sebda S, Quief S, Villenet C, Figeac M, Preudhomme C. High-throughput sequencing in acute lymphoblastic leukemia: follow-up of minimal residual disease and emergence of new clones. Leuk Res. 2017;53:1–7.

    Article  CAS  PubMed  Google Scholar 

  77. Van Dongen JJ, Langerak AW, Brüggemann M, Evans PAS, Hummer M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, Gonzelez M, Perreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–317.

    Article  PubMed  Google Scholar 

  78. Van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–28.

    Article  PubMed  Google Scholar 

  79. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwalde D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thinon X, Pradel V, Gonzalez M, Viehmann S, Malec M, Saglio G, van Dongen JJ. Standardization and quality control studies of real time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia. 2006;20:886–8.

    Article  Google Scholar 

  80. Gandemer V, Pochon C, Oger E, Dalle JHH, Michel G, Schmitt C, Berranger E, Galambrun C, Cave H, Cayuela M, Grardel N, Macintyre E, Margueritte G, Mechinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poiree M, Bordigoni P. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol. Br J Haematol. 2014;165(3):392–401.

    Article  PubMed  Google Scholar 

  81. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O’Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Cave H, van der Werff Ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E, Nelken B, Fournier M, Boutard P, Lebrun E, Mechinaud F, Garand R, Robert A, Dastugue N, Plouvier E, Racadot E, Ferster A, Gyselinck J, Fenneteau O, Duval M, Slbu G, Manel AM. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med. 1998;339(9):591–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, Graz, 8036, Austria

    Hildegard T. Greinix M.D

Authors
  1. Hildegard T. Greinix M.D
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hildegard T. Greinix M.D .

Editor information

Editors and Affiliations

  1. Eurocord Hôpital Saint Louis, Paris, France

    Éliane Gluckman

  2. Department of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany

    Dietger Niederwieser

  3. Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

    Mahmoud Aljurf

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Greinix, H.T. (2018). Laboratory Support. In: Gluckman, É., Niederwieser, D., Aljurf, M. (eds) Establishing a Hematopoietic Stem Cell Transplantation Unit . Springer, Cham. https://doi.org/10.1007/978-3-319-59358-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59358-6_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59356-2

  • Online ISBN: 978-3-319-59358-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation